


ParkwayHealth to process 4000 diagnostic tests per day in Singapore

23 October 2020 | News

The RESOLUTE 2.0 diagnostic test is an industry-first direct multiplex RT-PCR COVID-19 test kit co-developed by ASTAR



Singapore based Advanced MedTech Holdings (AMTH), a global medical technology leader, has recently announced the installation of the Rapid Automated Volume Enhancer (RAVE) robotics laboratory system in ParkwayHealth Laboratory.

Utilizing just two RAVE systems optimized for use with AMTH's RESOLUTE 2.0 RT-PCR test for SARS-CoV-2, ParkwayHealth Laboratory can now process an additional 4,000 diagnostics tests per day in Singapore.

Distributed by AMTH, the made-in-Singapore RAVE system minimizes the manual steps in the preparation of a test assay, shortening the time to results. RAVE was designed and co-developed by the Advanced Remanufacturing and Technology Centre (ARTC), and the Singapore Institute of Manufacturing Technology of the Agency for Science, Technology and Research (ASTAR), as well as the national platform Diagnostics Development (DxD) Hub. ARTC partner and local SME Sankei Eagle is the first local systems integrator for RAVE.

The RESOLUTE 2.0 diagnostic test is an industry-first direct multiplex RT-PCR COVID-19 test kit co-developed by ASTAR and DSO National Laboratories, manufactured and distributed by AMTH.

Parkway Pantai is one of Asia's largest integrated private healthcare providers operating in Malaysia, Singapore, India, Greater China and Brunei.

ParkwayHealth Laboratory has laboratories on the premises of Gleneagles, Mount Elizabeth, Mount Elizabeth Novena and Parkway East, the four private hospitals owned by Parkway Pantai, and a reference laboratory and headquarters located in Aljunied. ParkwayHealth Laboratory was the first private laboratory in Singapore to be approved by the Ministry of Health to run SARS-CoV-2 PCR tests for COVID-19 testing.